Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Opportunities to Optimize Cancer Policies Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Sep
03
Today In Oncology
ACS Publishes Report on Cancers in Asian American, Native Hawaiian, and Pacific Islander People
The 2026 ASCO Annual Meeting Geriatric Oncology Update: The Next Challenge Is Implementation
MD Anderson President Announces Retirement, Shares Leadership Transition Plans
ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next Treatment
Spartalizumab-Based Triplet Improves Long-Term Overall Survival in BRAF V600–Mutant Melanoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo